Walleye Capital
ITOS

Walleye Capital’s iTeos Therapeutics ITOS Stock Holding History

Walleye Capital’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-68,891
Closed -$2.22M – 2536
2022
Q1 		$2.22M Buy
68,891
+34,638
+101% +$1.26M 0.06% 342
2021
Q4 		$1.59M Buy
+34,253
New +$1.14M 0.05% 388

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Walleye Capital's ITOS Position: Q2 2022 in Review

Walleye Capital sold out of iTeos Therapeutics (ITOS) in Q2 2022, closing a stake of 68,891 shares — an estimated $2.22M sold.

Walleye Capital first reported a position in ITOS in Q4 2021 and held it in 2 quarters. The position peaked at $2.22M in Q1 2022. 152 funds tracked by Wall St. Rank hold ITOS as of Q2 2022.

  • Walleye Capital reported no remaining iTeos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Walleye Capital sold 68,891 iTeos Therapeutics shares in Q2 2022, an estimated $2.22M.
  • Walleye Capital first reported a position in iTeos Therapeutics in Q4 2021 and held it in 2 quarters.
  • Walleye Capital's iTeos Therapeutics position peaked at $2.22M in Q1 2022.
  • 152 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.